SCHEMBL1713754

SCHEMBL1713754

CN(C)C(=O)N1CCC2(CCN(Cc3ccccc3)CC2)c2ccccc21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.53
HDAC6 Q9UBN7 3/20 0.53
SIGMAR1 Q99720 11/20 0.52
CYP2D6 P10635 4/20 0.52
TP53 P04637 2/20 0.52
CYP1A2 P05177 2/20 0.52
CYP3A4 P08684 2/20 0.52
TSHR P16473 2/20 0.52
CYP2C19 P33261 2/20 0.52
ALDH1A1 P00352 2/20 0.52
CYP2C9 P11712 1/20 0.52
HDAC8 Q9BY41 1/20 0.51
DRD2 P14416 1/20 0.50
NFKB1 P19838 1/20 0.50
HTR2A P28223 1/20 0.50
HTR2C P28335 1/20 0.50
MAPK1 P28482 1/20 0.50
HTR2B P41595 1/20 0.50
MTOR P42345 1/20 0.50
MEN1 O00255 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1713006 0.88 CYP2D6 (0.56) HDAC1HDAC6SIGMAR1CYP2D6TP53
SCHEMBL23289929 0.84 HDAC1 (0.64) HDAC1HDAC6SIGMAR1CYP2D6TP53
SCHEMBL12316015 0.81 NOTUM (0.46) HDAC1HDAC6HDAC8
SCHEMBL30733409 0.81 HDAC1 (0.59) HDAC1HDAC6SIGMAR1CYP2D6TP53
SCHEMBL12460099 0.78 HDAC1 (0.39) HDAC1HDAC6SIGMAR1HDAC8DRD2
SCHEMBL13203987 0.78 NOTUM (0.42) HDAC1HDAC6SIGMAR1CYP2D6TP53
SCHEMBL13203978 0.77 SIGMAR1 (0.55) SIGMAR1
SCHEMBL13309551 0.76 HDAC1 (0.56) HDAC1HDAC6SIGMAR1CYP2D6TP53
SCHEMBL30733410 0.75 HDAC1 (0.58) HDAC1HDAC6SIGMAR1CYP2D6TP53
SCHEMBL1980590 0.75 HDAC1 (0.68) HDAC1HDAC6SIGMAR1CYP2D6TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263605-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICAL INCORPORATED (US) 2012-09-11 US disclosed
US-8263605-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICAL INCORPORATED (US) 2012-09-11 US disclosed
US-8263605-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICAL INCORPORATED (US) 2012-09-11 US disclosed
EP-1987034-B1 SPIRO CONDENSED PIPERIDINES AS MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMA (US) 2011-07-20 EP disclosed
EP-1987034-B1 SPIRO CONDENSED PIPERIDINES AS MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMA (US) 2011-07-20 EP disclosed
US-20090227614-A1 Modulators of Muscarinic Receptors VERTEX PHARMACEUTICALS INCORPORATED 2009-09-10 US disclosed
US-20090227614-A1 Modulators of Muscarinic Receptors VERTEX PHARMACEUTICALS INCORPORATED 2009-09-10 US disclosed
US-20090227614-A1 Modulators of Muscarinic Receptors VERTEX PHARMACEUTICALS INCORPORATED 2009-09-10 US disclosed
WO-2007100670-A1 SPIRO CONDENSED PIPERIDNES AS MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227614-A1 Modulators of Muscarinic Receptors CHRM5, CHRM3, CHRM2 HDAC1 1593/4885HDAC6 1555/4885SIGMAR1 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.